Target drug delivery system as a new scarring modulation after glaucoma filtration surgery by Tingting Shao et al.
HYPOTHESIS Open Access
Target drug delivery system as a new scarring
modulation after glaucoma filtration surgery
Tingting Shao1†, Xiaoning Li2† and Jian Ge2*
Abstract
Background: Excessive wound healing following glaucoma filtration surgery is the main determinant of surgical
failure, resulting from the activation of human Tenon’s capsule fibroblasts (HTFs). To mitigate the excessive wound
healing, the topicall use of antiproliferative agents, such as mitomycin C (MMC) and 5-fluorouracil (5-FU), has
increased the surgery success rate, but the traditional administration of these agents can result in a variety of
toxicities with nonspecific damage. However, modulation of the wound healing process to prevent excessive
fibroblast proliferation and scar formation can play a major role in improving the outcome of surgery. Therefore,
the search for alternative modes of drug delivery and new agents is needed to minimize the ocular complications
and improve the success of surgery. We have shown that there is a postoperative overexpression of the LDL
receptor (LDLr) in the activated HTFs may provide a novel target for drug delivery systems.
Presentation of the Hypothesis: We hypothesize that antifibrotic agents (MMC) encapsulated in LDLr targeting
drug delivery system (LDL-MMC-chitosan nanoparticles) may be proposed in anti-scarring therapy to increase the
safety and effectiveness and to reduce toxicity.
Testing the Hypothesis: A chitosan-based polymeric predrug of MMC was synthesized and its cytotoxicity was
proved to be low. In addition, we propose hyaluronic acid film as a container to release LDL-MMC-chitosan
nanoparticles gradually at subconjunctival filtering site after glaucoma filtration surgery to eliminate the LDL-MMC-
chitosan nanoparticles.
Implications of the Hypothesis and discussion: This strategy can be applicable to anti-scarring therapy during
excessive conjunctival wound healing. This hypothesis integrates advantages of the targeting drug delivery and
antifibrotic agents, such as high efficiency, convenience, and lower the toxicity.
Background
The most common cause of glaucoma filtration sur-
gery failure is excessive scar formation at the surgical
site[1,2]. The activation of HTFs is believed to be
responsible for this problem[3,4], and local use of
antiproliferative agents, such as mitomycin C (MMC)
and 5-fluorouracil (5-FU), has improved the surgical
success by preventing HTFs proliferation and scar for-
mation. The traditional administration of these agents
maintain the patency of the new filtration pathway.
However, filtering blebs treated with these agents can
still fail through scarring and because of their nonspe-
cific mechanisms of action[5,6], these agents can cause
widespread cell death and apoptosis. Thus, the tradi-
tional administration of these agents topically can
result in a variety of complications, including blebitis,
endophthalmitis, corneal epithelial defects, and hypot-
ony with accompanying vision loss[7,8]. It is clinically
well known that chronic tissue effects of antifibrotics
(ie, to the conjunctiva) can occur for many years after
a single topical application. Some authors argued that
the toxicity of MMC to the ciliary epithelium might be
an important contributor to its IOP lowering effect[9].
Because the antifibrotic agents are relatively nonspeci-
fic and react with cells in every phase in the cell cycle,
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These problems have stimulated the search for alter-
native modes of drug delivery and new agents to mini-
mize the ocular complications[11]. Numerous implants
that release MMC continuously have been investigated
to avoid the naturally occurring scarring but cannot
localize the side effects of the agent[12-14], for they can-
not lower the toxicity to non-proliferating cells.
Recently, studies have shown that constant nanoparticle
drug delivery to targeted tissues and cells may offer a
greater therapeutic effect than traditional dosing meth-
ods[15,16]. The results of other studies suggested that
photosensitizer accumulates mainly inside the activated
HTFs via the overexpressed LDLr to absorbs light and
generates cytotoxic reactive oxygen species leading to
cellular damage[17]. This result is confirmed in vivo by
an investigation, using the photodynamic therapy (PDT)
for anti-scarring after glaucoma filtering surgery [18].
Perhaps the most successful approval of PDT is with
photosensitizer for injection (Visudyne) to treat age-
related macular degeneration (AMD).
LDLr is a single-chain transmembrane glycoprotein
that specifically mediates binding and endocytosis of
LDL. Receptor-mediated endocytosis is a highly specific,
high capacity process that can absorb a large amount of
LDL into the cell within a relatively short time. Once
internalized, LDLr dissociates from LDL and is recycled
back to the cell surface where it is available to interact
with many more LDL over its lifetime[19]. Then LDL
are retained and accumulated in the sorting endosome.
Therefore, any agent that can be attached to LDL can
also be internalized and accumulate within LDLr expres-
sing cells. In fact, the expression of the LDL receptors
on the cell surface is regulated by the need of the cell
for cholesterol[20]. It is known that rapidly proliferating
tissues have a high demand for cholesterol for cell mem-
brane synthesis. Increases of 3- to 100-fold in expression
of LDLr over corresponding non-malignant tissues have
been reported in acute myelogenous leukemia, colon
cancer, adrenal adenoma, lung carcinoma, breast cancer,
and prostate cancer[19,21].
Our previous study have shown that the LDLr are
overexpressed in the activated HTFs[22]. As we showed,
the LDLr protein in activated HTFs is 8-fold higher
than that of normal HTFs, and the fluorescence of Dio-
labeled LDL particles uptaked by activated HTFs is
3.73-fold higher than that of the normal HTFs. There-
fore, we propose that the LDLr is a potential molecular
target for the selective delivery of anti-scarring therapy
during excessive conjunctival wound healing.
Presentation of hypothesis
We propose that MMC encapsulated into LDL-chitosan
nanoparticles (LDL-MMC-chitosan nanoparticles) will
be an effective way to deliver MMC specifically to
HTFs. The MMC-chitosan nanoparticles will be made
as reports[23,24]. The nanocontainers are synthesized by
well biodegradable, biocompatible, nonimmunogenic
chitosan. Chitosan and its derivatives draw attention as
a drug delivery vehicle. Especially, ordinary chitosan can
be dissolved in acidic water but not in alkaline, that
means the nanocontainers would degrade in the sorting
endosome and release the MMC. Chitosan can easily
react with many kinds of agents due to having -NH2
and -COOH groups in its structure, which is valuable
for the drug carrier to readily prepare its conjugates
with various drugs to avoid vexatious complications.
That is possible to deal with the application of chitosan
as a carrier for water-insoluble and water-soluble drug
conjugates in anti-scarring therapy. Izume summarized
the toxicity of chitosan including a skin sensitization
study, temporal skin irritation study, ophthalmic sensiti-
zation test, mutagenicity test and patch test for humans;
every study and test showed low toxicity of chitosan,
which can function well as a drug carrier due to long
systemic retention, low toxicity and accumulation in the
target tissue[24-26].
In addition, firstly, nanoparticles increase uptake into
activated HTFs that overexpressed LDLr, and steady
release MMC. Secondly, chitosan nanoparticles confine
and protect the enclosed MMC which may be hydrophi-
lic until they bind to the outer membrane of the tar-
geted HTFs, and lower effective dose of MMC. Thirdly,
chitosan nanoparticles have the capability of keeping
stability in human body. And finally, the scale dimen-
sions of nanoparticles are between 1 and 100 nm, which
favor endocytosis via LDLr.
The LDL particle is a naturally occurring nanostruc-
ture typically with a diameter of 22 nm. It contains a
lipid core of some 1500 esterified cholesterol molecules
and triglycerides. A shell of phospholipids and unesteri-
fied cholesterol surrounds this highly hydrophobic core.
The shell also contains a single copy of apoB-100, which
is recognized by the LDLr[25]. As reported that there
are three ways to interact with LDL[19]: (1) via attach-
ment to the apoB-100 protein on the surface of LDL,
(2) via intercalation into the phospholipid monolayer of
LDL, and (3) via substitution of the agent in the lipid
core of LDL. Therefore, we can combine LDL and
MMC-chitosan nanoparticle by one of the three strate-
gies above.
Testing the hypothesis
To test this hypothesis, a chitosan-based polymeric pre-
drug of MMC was synthesized and the drug release
rates were controlled by the aldehyde degree of chitosan
and the mass ratios of periodate-oxidized chitosan (CS-
CHO) to MMC (mCS-CHO/mMMC). When the mCS-CHO/
mMMC was 5/1, 10/1 and 25/1, the initial release amount
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of MMC was 65%, 50% and 45%. There was an obvious
initial release within the initial 8 h, and the concentra-
tion of MMC in dialysis medium remained unchanged
during the following 60 h. Furthermore, the cytotoxicity
study on chitosan-based polymeric predrug encapsulated
fibroblast indicated that the maximum non-toxic con-
centration of CS-CHO was 8.3, 42.3 and 54.7 mg/ml in
the 24, 48 and 72 h[26]. Therefore, the concentration of
CS-CHO in the practical application should be lower
than the corresponding concentration. In vitro, chito-
san-based polymeric predrug of MMC was a low cyto-
toxic controlled delivery system.
In addition, we plan to insert LDL-MMC-chitosan
nanoparticles into hyaluronic acid film (80 μm
thickness) (Figure 1), which has no toxicity[27]. In glau-
coma filtration surgery, the conjunctival wound is
sutured with subconjunctival implantation of the hya-
luronic acid film at the filtering site. In terms of physical
characteristics, hyaluronic acid film changes from solid
form into gel form within 24 to 48 hours in the tissue
and stays within the tissue for about 7 to 14 days. How-
ever, it has been generally reported that fibroblasts
increase the most at 4 to 7 days postoperatively.
Furthermore, this film material functions as a barrier to
contact between separated tissues by which the post-
operative formation of adhesions is reduced and delayed,
and no subsequent removal procedure is required. With
the gradual degradation of hyaluronic acid film in the
Figure 1 LDL-MMC-chitosan nanoparticles release from hyaluronic acid film. The hyaluronic acid film is implanted into subconjunctival
space at the filtering site, with conjunctival wound is sutured, and LDL-MMC-chitosan nanoparticles release constantly from the hyaluronic acid
film. LDL-MMC-chitosan nanoparticles is made by chitosan nanocontainer encapsulating MMC, and then combined with LDL.
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body, the LDL-MMC-chitosan nanoparticles will be
released into the subconjunctival space, and endocytosed
mainly by activated HTFs at wound site.
We will observe the validity of creating a long-term
effective filtering bleb and decrease of the ocular com-
plications, compared with the control. The encapsula-
tion allows constant release rather than a burst of drugs
so that a high therapeutic efficiency can be achieved
without side effects. The LDL-MMC-chitosan nanoparti-
cles drug delivery system is proposed based on the LDL
receptor endocytosis pathway. The receptor-mediated
uptake mechanism is an interesting aspect of the LDLr
system. Receptor-mediated endocytosis is a highly speci-
fic, high capacity process that can absorb a large amount
of LDL-MMC-chitosan nanoparticles into the activated
HTFs within a relatively short time. Once internalized,
LDLr dissociates from LDL-MMC-chitosan nanoparti-
cles and is recycled back to the cell surface where it is
available to interact with many more LDL-MMC-chito-
san nanoparticles over its lifetime. With a recycle time
of approximately 10 min and a lifetime of about 24 h,
one can assume that each receptor mediates the trans-
port of about 144 LDL-MMC-chitosan nanoparticles
into the activated HTFs per day. Assuming about 1,000
receptors per cell, this provides an extremely efficient
system for delivering its MMC. Therefore, LDL-MMC-
chitosan nanoparticles accumulate mainly within the
activated HTFs instead of bring nonspecific toxicity to
both proliferating and non-proliferating cells.
Implications of the Hypothesis and discussion
In this article, we propose LDL-MMC-nanoparticles as a
consistent drug delivery system that specifically bind to
LDLr mainly in activated HTFs. This may achieve a
long circulation time, low immunogenicity, good bio-
compatibility, highly selective targeting, lower drug dose,
reduced toxicity to normal cells, and increased safety
and effectiveness of anti-scarring therapy during exces-
sive conjunctival wound healing.
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